Watch, but Do Not Wait: On the Ebola PHEIC

Editorial Summary: The Hindu argues that WHO’s May 17, 2026 PHEIC declaration over Bundibugyo ebolavirus in DRC and Uganda demands active Indian preparedness, not passive monitoring. Bundibugyo strain has no licensed vaccine and no approved antiviral — making surveillance, rapid diagnosis, and isolation the only tools available. India’s post-COVID infrastructure has improved, but critical gaps remain: single BSL-4 laboratory at NIV Pune, no domestic BVD PCR kit, and untested VHF contact-tracing protocols. The editorial recommends funding CEPI vaccine candidates, expanding BSL-3 capacity, and pre-positioning PPE at international airports.

The PHEIC and What It Means

On May 17, 2026, WHO Director-General declared a Public Health Emergency of International Concern (PHEIC) — the highest alert level in global health governance — for an outbreak of Bundibugyo ebolavirus (BDBV) spanning Ituri Province, Democratic Republic of Congo and, critically, Kampala, Uganda’s capital.

The urban geography of the Kampala cases is the trigger. BDBV has appeared in DRC before. But when a haemorrhagic fever virus reaches an international airport city — Entebbe International Airport is 35 km from Kampala — the import risk calculation changes.

What makes a PHEIC? Under IHR 2005 Article 12, the WHO Director-General declares a PHEIC when three criteria are met:

1. The event constitutes a public health risk through international spread.
2. It is unusual or unexpected.
3. It may require a coordinated international response.

The PHEIC declaration obligates all IHR signatory states — including India — to activate surveillance, screen travellers from affected areas, and share data with WHO. It is not a travel ban; it is a preparedness mandate.

Why Bundibugyo Is Harder Than Zaire

Not all ebolavirus species are equal. The five recognised species — Zaire, Sudan, Bundibugyo, Reston, Tai Forest — differ in transmissibility, case fatality rates, and critically, in available countermeasures.

The absence of a licensed BDBV vaccine and the absence of approved antivirals means that the entire public health response depends on surveillance, case identification, isolation, and contact tracing — all functions that require strong health system infrastructure at the point of first contact. There is no prophylactic backstop.

CEPI (Coalition for Epidemic Preparedness Innovations) — co-funded by India, Wellcome, Bill & Melinda Gates Foundation, and the UK/Norwegian governments — has BDBV vaccine candidates at early clinical stages under the 100-Days Mission framework. But these candidates are at least 18–24 months from efficacy data.

India’s Risk: Low but Not Zero

India’s direct risk from this PHEIC is low but identifiable.

Air connectivity: India has no direct air routes to DRC. Kampala (Uganda) is connected to India via Gulf hubs — Dubai (EK), Doha (QR), Abu Dhabi (EY). A traveller from Kampala to Mumbai or Delhi changes aircraft in the Gulf, arriving at Chhatrapati Shivaji Maharaj International or Indira Gandhi International airports — both of which have Port Health Offices but no Ebola-specific triage protocols.

Indian diaspora: India’s diaspora in East Africa is approximately 3 million persons, concentrated in Kenya, Tanzania, Uganda, and Rwanda. Travel volumes are not large by intra-Asia standards but are not negligible — estimated 300,000–400,000 India-East Africa passenger journeys per year in both directions.

Incubation ceiling: Bundibugyo ebolavirus has an incubation period of 2–21 days. A traveller who becomes infected on their last day in Uganda could arrive in India presymptomatic and become ill 1–20 days later, potentially after reaching a district hospital far from any BSL-3 facility.

India’s VHF Preparedness Framework — and Its Gaps

India’s framework for managing Viral Haemorrhagic Fevers (VHFs) rests on several overlapping structures:

Gap 1: Geographical BSL-4 Coverage

India’s BSL-4 facility at ICMR-NIV Pune is the sole civilian high-containment laboratory capable of handling live Ebola virus for research and confirmatory testing (a DRDO BSL-4 exists at Gwalior but serves defence research). For a traveller arriving at Kolkata, Chennai, Ahmedabad, or Hyderabad with suspected Ebola, the specimen must be transported — under specialised transport conditions — to Pune. This adds 12–24 hours to diagnosis and requires managing the patient under PUI (Patient Under Investigation) protocols at a general hospital that may not have adequate biocontainment capacity.

Gap 2: No Domestic BVD Diagnostic Kit

India has no domestically manufactured PCR diagnostic kit specific to Bundibugyo ebolavirus. Confirmatory testing at NIV Pune uses imported reagents and WHO-validated protocols. In a surge scenario where multiple airports are simultaneously managing suspect cases, imported reagent supply chains could become a bottleneck — the same bottleneck that emerged with COVID RT-PCR kits in early 2020.

Gap 3: VHF Contact Tracing Protocols

COVID contact tracing in India was based on close proximity (the Aarogya Setu model). Ebola contact tracing is fundamentally different: transmission requires direct contact with body fluids from a symptomatic patient. Ebola contact tracing must reconstruct:

• Healthcare worker exposure events
• Burial practices (traditional washing of bodies is a major transmission pathway)
• Household caregiving dynamics
• Market/bushmeat handling exposure (for spillover identification)

These are qualitatively different from COVID contact tracing, and IDSP’s VHF-specific contact tracing algorithm has not been publicly tested or validated in India since the 2018 Nipah response in Kerala — which, while commendable, involved a different pathogen and a much smaller geographic scope.

The One Health Dimension

BDBV spillover — like most emerging zoonotic infections — is a One Health problem. The WHO-FAO-UNEP-WOAH Quadripartite One Health framework identifies three drivers of spillover:

1. Deforestation that shrinks wildlife habitat and pushes human activity into bat roosting areas.
2. Bushmeat hunting and handling — the primary mode of primary spillover.
3. Weak veterinary-human health interface at rural health centres where zoonotic cases first present.

India is not immune to this dynamic. Nipah virus (natural reservoir: Indian flying fox Pteropus medius) has caused outbreaks in Kerala in 2018, 2021, and 2023. Kyasanur Forest Disease (KFD) — a tick-borne VHF — is endemic in Karnataka and expanding geographically. The One Health lesson is that investment in India’s own zoonotic surveillance benefits India’s global preparedness posture as well — the IDSP-VHF module proposed here is not charity to Africa; it is self-interest.

What India Should Do

1. Fund CEPI’s BDBV vaccine programme. India is already a CEPI contributor. Earmarking additional funds for Bundibugyo-specific vaccine candidates advances the 100-Days Mission and places India among co-developers, with preferential access to doses in an outbreak scenario.

2. Expand BSL-3 capacity to regional hubs. Four additional hospitals — AIIMS Kolkata (East), PGIMER Chandigarh (North), NIMHANS Bengaluru (South), AIIMS Bhopal (Central) — should be upgraded to BSL-3 with VHF isolation capacity. Capital investment is approximately ₹50–80 crore per facility; operationally modest relative to the insurance value.

3. Pre-position PPE at international airports. The four airports with highest East Africa connectivity — Indira Gandhi (Delhi), CSIA (Mumbai), Kempegowda (Bengaluru), Rajiv Gandhi (Hyderabad) — should have PPE stockpiles for 20 simultaneous PUI cases. This is logistics, not science.

4. Establish an NCDC-WHO IDSP-VHF module. A joint NCDC-WHO technical working group should develop, test, and publish a VHF-specific contact tracing protocol within 90 days. The protocol should be uploaded to the IDSP portal and made mandatory for district-level outbreak investigation officers.

5. Publish a National One Health Action Plan. India’s National Action Plan for Antimicrobial Resistance (NAP-AMR) is a model. A comparable National One Health Action Plan for Zoonotic Disease Surveillance — mapping deforestation risk corridors, veterinary-human health interface points, and laboratory referral chains — would institutionalise the cross-sectoral coordination that individual outbreak responses currently recreate from scratch.

UPSC Mains Analysis

GS Paper 2 — Governance/International bodies | GS Paper 3 — Science & Technology, Environment

Key arguments:

• BDBV has no licensed vaccine and no approved antiviral — India’s entire risk management rests on surveillance and containment capacity, not prophylaxis.
• Post-COVID IDSP improvements are insufficient for VHF-specific contact tracing, which requires reconstruction of body-fluid exposure events rather than proximity contacts.
• Single BSL-4 laboratory at NIV Pune is a structural vulnerability; surge scenarios with multiple suspected cases require geographically distributed high-containment capacity.

Counterarguments:

• India’s direct Ebola risk is extremely low; diverting health infrastructure investment toward a low-probability exotic pathogen may crowd out investment in high-burden endemic diseases.
• PHEIC declarations have sometimes triggered disproportionate responses (e.g., WHO PHEIC for H1N1 in 2009 was criticised as premature) — calibrated monitoring rather than mobilisation may be appropriate.

Mains Keywords: PHEIC, IHR 2005 Article 12, Bundibugyo ebolavirus (BDBV), Zaire ebolavirus (EBOV), Ervebo vaccine, CEPI 100-Days Mission, ICMR-NIV Pune BSL-4, IDSP, NCDC, One Health Quadripartite (WHO-FAO-UNEP-WOAH), VHF contact tracing, port health officers, Epidemic Diseases Act 1897, Nipah virus, Kyasanur Forest Disease, ring vaccination.

Prelims Facts Corner

Editorial Insight

The Hindu’s editorial case is simple and urgent: “watch but do not wait” is the governing principle. India has been through COVID; it knows the price of a surveillance gap that is discovered only when the patient is already in an ICU. Bundibugyo Ebola is low-probability for India — but low probability multiplied by no licensed vaccine, single BSL-4 laboratory, and untested VHF contact-tracing protocols equals a risk that responsible preparedness planning cannot ignore. The time to fill the gaps is now, not after the first confirmed case.

Sources: The Hindu, WHO, PIB, ICMR